Patents Assigned to CardioPep Pharma GmbH
  • USE OF URODILATIN FOR PREPARING A MEDICAMENT FOR THE TREATMENT OF CARDIOVASCULAR, RENAL, PULMONARY AND NEURONAL SYNDROME WHILE AVOIDING A REBOUND
    Publication number: 20150051382
    Abstract: Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound, wherein said medicament for the delivery of urodilatin is suitable in a first quantity for a first period of at least 48 hours, followed by delivery over a second period of at least 12 hours with successive reduction of said first quantity continuously or gradually to 0 ng/kg/min.
    Type: Application
    Filed: April 16, 2014
    Publication date: February 19, 2015
    Applicant: CARDIOPEP PHARMA GMBH
    Inventor: Wolf-Georg FORSSMANN
  • Use of natriuretic peptide for treating heart failure
    Patent number: 8710006
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: April 29, 2014
    Assignee: Cardiopep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler
  • Use of Natriuretic Peptide for Treating Heart Failure
    Publication number: 20110257099
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 20, 2011
    Applicant: CARDIOPEP PHARMA GMBH
    Inventors: Veselin Mitrovic, Hartmut L?ss, Wolf-Georg Forssmann, Markus Meyer, Klaus D?hler
  • Use of natriuretic peptide for treating heart failure
    Patent number: 7732406
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: June 8, 2010
    Assignee: CardioPep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Lüss, Wolf-Georg Forssmann, Markus Meyer, Klaus Döhler
  • Use of natriuretic peptide for treating heart failure
    Publication number: 20060264376
    Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.
    Type: Application
    Filed: April 7, 2006
    Publication date: November 23, 2006
    Applicant: Cardiopep Pharma GmbH
    Inventors: Veselin Mitrovic, Hartmut Luss, Wolf-Georg Forssmann, Markus Meyer, Klaus Dohler